JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morris, L. E.
Right arrow Articles by White, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morris, L. E.
Right arrow Articles by White, J. M., Jr.
Journal of Pharmacology And Experimental Therapeutics, Vol. 106, Issue 1, 49-54, 1952
Copyright © 1952 by American Society for Pharmacology and Experimental Therapeutics


LABORATORY AND CLINICAL OBSERVATIONS ON THE EFFECT OF REGITINE (C-7337) ON CARDIAC IRREGULARITIES DURING CYCLOPROPANE ANESTHESIA

Lucien E. Morris 1, Chung Sang Yein 1, Bruno Haid 1, and J. M. White Jr. 1

1 Division of Anesthesiology, Department of Surgery, State University of Iowa College of Medicine, Iowa City, Iowa

Regitine reduces the incidence of cyclopropane-epinephrine induced ventricular tachycardia in the dog.

In the dosage in which Regitine was used as premedication before cyclopropane anesthesia in 23 patients there was no significant reduction in ventricular irregularities as compared with the control group. The incidence of ventricular irregularities did not seem to be significantly altered by injection of Regitine during anesthesia.

Submitted on April 21, 1952







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1952 by the American Society for Pharmacology and Experimental Therapeutics.